Published in J Hepatol on September 24, 2007
Overview of immunosuppression in liver transplantation. World J Gastroenterol (2009) 0.96
Living-donor liver transplantation and hepatitis C. HPB Surg (2013) 0.90
Management of recurrent hepatitis C following liver transplantation. Gastroenterol Hepatol (N Y) (2010) 0.89
Current status of immunosuppression in liver transplantation. J Clin Exp Hepatol (2013) 0.86
A comprehensive review of immunosuppression used for liver transplantation. J Transplant (2009) 0.86
Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review. J Clin Transl Hepatol (2015) 0.86
New insights in recurrent HCV infection after liver transplantation. Clin Dev Immunol (2013) 0.83
Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem. World J Gastroenterol (2014) 0.83
Strategies to reduce hepatitis C virus recurrence after liver transplantation. World J Hepatol (2013) 0.82
Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes. Gut (2013) 0.82
Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future. World J Gastroenterol (2014) 0.81
A Randomized Multicenter Study Comparing a Tacrolimus-Based Protocol with and without Steroids in HCV-Positive Liver Allograft Recipients. J Transplant (2012) 0.80
Liver transplantation and hepatitis C. Int J Hepatol (2012) 0.79
Role of steroid minimization in the tacrolimus-based immunosuppressive regimen for liver transplant recipients: a systematic review and meta-analysis of prospective randomized controlled trials. Hepatol Int (2014) 0.78
Virus-drug interactions--molecular insight into immunosuppression and HCV. Nat Rev Gastroenterol Hepatol (2012) 0.77
HCV in liver transplantation. Semin Immunopathol (2012) 0.76
Steroids in recurrent hepatitis C following liver transplantation: pitfall or panacea? J Hepatol (2007) 0.76
Fibrosing cholestatic hepatitis C in post-transplant adult recipients of liver transplantation. Ann Gastroenterol (2016) 0.75
Prevention of hepatitis C recurrence after liver transplantation: An update. World J Gastrointest Pharmacol Ther (2012) 0.75
Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients. Hepat Med (2011) 0.75
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res (2007) 5.40
Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol (2003) 5.17
Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol (2006) 3.65
Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology (2010) 3.53
Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol (2006) 3.09
A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology (2004) 2.70
Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol (2006) 2.61
Transjugular liver biopsy--indications, adequacy, quality of specimens, and complications--a systematic review. J Hepatol (2007) 2.52
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology (2009) 2.45
Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol (2010) 2.41
Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol (2008) 2.36
MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res (2010) 2.28
Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma. Ann Surg (2012) 2.27
Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: a systematic review. Transplantation (2012) 2.26
Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int (2014) 2.26
Ovarian metastasis from colorectal cancer: prognostic value of radical oophorectomy. J Surg Oncol (2007) 2.25
Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int (2014) 2.23
TIPS for refractory ascites: a single-centre experience. J Gastroenterol (2009) 2.19
The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol (2004) 2.18
Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl (2002) 2.18
Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis. Hepatology (2013) 2.16
MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res (2009) 2.16
When to perform hepatic resection for intermediate-stage hepatocellular carcinoma. Hepatology (2015) 2.15
The role of liver resections for noncolorectal, nonneuroendocrine metastases: experience with 142 observed cases. Ann Surg Oncol (2005) 2.13
Long-term outcome of bone mineral density in children who underwent a successful liver transplantation. Transplantation (2004) 2.04
Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl (2005) 2.04
Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. Lancet Oncol (2011) 2.04
Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg (2003) 2.03
Does portal-superior mesenteric vein invasion still indicate irresectability for pancreatic carcinoma? Ann Surg Oncol (2009) 2.02
Hepatitis C virus infection in end-stage renal disease and kidney transplantation. Transpl Int (2014) 2.01
A randomized study comparing ligation with propranolol for primary prophylaxis of variceal bleeding in candidates for liver transplantation. Liver Transpl (2007) 2.01
Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol (2008) 1.98
Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation (2002) 1.95
Esophagogastric junction gastrointestinal stromal tumor: resection vs enucleation. World J Gastroenterol (2010) 1.92
A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology (2009) 1.90
Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg (2004) 1.88
Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int (2012) 1.87
Different methods of creatinine measurement significantly affect MELD scores. Liver Transpl (2007) 1.87
Hepatocyte transplantation as a treatment for glycogen storage disease type 1a. Lancet (2002) 1.86
Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol (2002) 1.85
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res (2009) 1.84
A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol (2007) 1.83
A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology (2009) 1.78
Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood (2002) 1.77
Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J (2012) 1.77
Subnormothermic machine perfusion protects steatotic livers against preservation injury: a potential for donor pool increase? Liver Transpl (2009) 1.75
Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. Liver Transpl (2008) 1.75
Trends in perioperative outcome after hepatic resection: analysis of 1500 consecutive unselected cases over 20 years. Ann Surg (2009) 1.73
A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transpl (2006) 1.73
Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl (2007) 1.68
Surgery versus conservative antibiotic treatment in acute appendicitis: a systematic review and meta-analysis of randomized controlled trials. Dig Surg (2011) 1.67
Liver transplantation for acute liver failure in Europe: outcomes over 20 years from the ELTR database. J Hepatol (2012) 1.66
Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg (2004) 1.65
Beyond "cirrhosis": a proposal from the International Liver Pathology Study Group. Am J Clin Pathol (2012) 1.65
Prognostic models in cirrhotics admitted to intensive care units better predict outcome when assessed at 48 h after admission. J Gastroenterol Hepatol (2007) 1.64
Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology (2006) 1.64
Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev (2006) 1.63
Can antiplatelet prophylaxis reduce the incidence of hepatic artery thrombosis after liver transplantation? Liver Transpl (2007) 1.61
Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation. Liver Transpl (2009) 1.60
Preliminary results of a "prope" tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation. Transplantation (2005) 1.59
Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut (2010) 1.59
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Human OX40 tunes the function of regulatory T cells in tumor and nontumor areas of hepatitis C virus-infected liver tissue. Hepatology (2014) 1.58
An updated follow-up of chronic hepatitis C after three decades of observation in pediatric patients cured of malignancy. Pediatr Blood Cancer (2010) 1.55
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis (2010) 1.54
The survival benefit of liver transplantation in hepatocellular carcinoma patients. Dig Liver Dis (2010) 1.53
Role of hepatitis B virus infection in the prognosis after hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a Western dual-center experience. Arch Surg (2009) 1.53
12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl (2006) 1.53
Kaposi's sarcoma in transplant and HIV-infected patients: an epidemiologic study in Italy and France. Transplantation (2005) 1.52